Empowered Funds LLC Acquires New Stake in TransMedics Group, Inc. $TMDX

Empowered Funds LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 48,154 shares of the company’s stock, valued at approximately $3,198,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TMDX. Royal Bank of Canada increased its stake in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after purchasing an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares in the last quarter. Finally, M&T Bank Corp acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $209,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Stock Down 3.1%

TMDX stock opened at $82.24 on Wednesday. The company’s 50 day moving average price is $79.40 and its 200 day moving average price is $92.84. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of 21.14 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter in the prior year, the firm earned $0.92 EPS. The firm’s revenue was up 20.7% compared to the same quarter last year. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research note on Wednesday, July 1st. Needham & Company LLC cut their price objective on TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Finally, Stifel Nicolaus lifted their target price on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, June 18th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $124.18.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.